# Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
> Sabunga O.D.

URL kanonis: https://discover.unhas.ac.id/publications/pub_scopus_85138883592
Jurnal / Konferensi: Asian Pacific Journal of Cancer Prevention
Tahun terbit: 2022
DOI: https://doi.org/10.31557/APJCP.2022.23.9.3051
ISSN: 15137368
Kuartil SJR: Q3
Citations: 3

## Authors
- Sabunga O.D.

## Abstract
OBJECTIVE: This study evaluated the differences between IDH1-R132H and CD133 expression in different categories of astrocytoma. MATERIAL AND METHODS: This study used a cross-sectional design. Sixty-seven paraffin embedded block of Diffuse Astrocytoma (DA), Anaplastic Astrocytoma (AA) and Glioblastoma (GB) were assessed using using the monoclonal antibody IDH1-R132H and Rabbit polyclonal antibody CD133. RESULTS: It was found that there was a significant relationship between the expression of IDH1-R132H and CD133 in DA, AA and GB (p<0.001). Astrocytoma with IDH-mutant molecular status will express more markers of cancer stem cell CD133 than IDH-wildtype. CONCLUSION: The IDH1-R132H and CD133 can provide predictive value on treatment success, disease prognosis, recurrence and can be considered as target combination therapy with chemotherapy.

## Keywords
- Isocitrate dehydrogenase
- IDH1
- Astrocytoma
- Anaplastic astrocytoma
- Monoclonal antibody
- Cancer research
- Cancer stem cell
- Glioma
- Polyclonal antibodies
- Immunohistochemistry
- Stem cell
- Antibody
- Biology
- Cancer
- Medicine
- Mutant
- Pathology
- Internal medicine
- Immunology
- Enzyme
- Biochemistry
- Gene
- Genetics

---
Sumber: Discover Unhas — RIMS Universitas Hasanuddin.
Saat mengutip, gunakan DOI bila tersedia atau URL kanonis di atas.